BN · rank #12 · 2026-10-22
EXENS
PARIS · EUR · $3.31B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of the factors below; drives the rank. | -0.35 |
|---|---|
| Forward revenue growth Consensus forward revenue growth. | +13.2% |
| Forward net margin Consensus forward net margin. | +6.6% |
| Net margin TTM Trailing twelve month net margin. | +6.0% |
| Margin expansion Forward minus trailing net margin (percentage points). | +0.6% |
| Forward PEG Forward P/E to growth. Below 1 is cheap for the growth. | — |
| Debt / FCF Net debt relative to free cash flow. Lower is safer. | 2.58× |
| Analyst upside Spread between the consensus 12m target and the current price. | +20.0% |
| Last EPS surprise Most recent reported EPS versus consensus. | — |
| Market cap (USD) | $3.31B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Exosens produces high-performance image-intensifier tubes, thermal and cooled-infrared cameras, and nuclear instrumentation for defense, surveillance, and industrial applications.
Rationale
Exosens acts as a critical, ITAR-free bottleneck solver for European defense night-vision supply chains, backed by strong forward revenue growth (13.2%) and a major September 2026 FY2026 guidance upgrade.
Material risks
- 1Defense system integrators could dual-source components or develop in-house night-vision and infrared capabilities, eroding Exosens's strategic ITAR-free component bottleneck.
- 2Execution, technology displacement, or qualification delays as the company aggressively expands thermal and cooled-infrared camera capacity.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.